GAE delivers lasting knee pain relief in 80% of patients — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Researchers led by Florian Nima Fleckenstein at Charité -- Universitätsmedizin Berlin reported that 80% of 194 osteoarthritis patients experienced clinically meaningful pain relief lasting at least 12 months after undergoing genicular artery embolization (GAE).
- The procedure uses rapidly resorbable gelatin-based microspheres injected through a thin catheter to block abnormal blood vessels around the knee; all 239 procedures were technically successful, with no moderate or severe adverse events recorded.
- Median pain scores fell from 7 before treatment to 3 at six months and held at 3 at the 12-month follow-up — more than a 50% reduction sustained for a full year.
- Quality of life scores climbed from 19 to 40 at 12 months, while daily-activity scores rose from 53 to 71.5 and sports-and-recreation scores more than doubled from 15 to 36.
- Researchers cautioned that the study did not demonstrate whether GAE prevents cartilage deterioration or reverses existing joint damage, leaving open whether the treatment alters disease progression or only addresses symptoms.
- Mild complications occurred in 6.7% of procedures — brief skin discoloration and one superficial blood collection at the catheter site — all of which resolved without lasting effects.
Why it matters: The 194-patient prospective study targets what its authors call a 'real treatment gap' between failed conservative care and joint replacement — a gap that affects the 365 million adults worldwide with knee osteoarthritis per WHO figures. An outpatient catheter procedure that halves pain and improves quality of life for at least a year could move earlier in the treatment sequence for patients who can't or won't undergo surgery, though the study did not test whether GAE actually slows cartilage loss.
Ask SkimNews
